Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 301 to 315 of 1037 results for criteria

  1. The social care guidance manual (PMG10)

    The social care guidance manual

  2. Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine (TA440)

    Evidence-based recommendations on pegylated liposomal irinotecan (Onivyde) for treating pancreatic cancer in adults.

  3. Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer (TA403)

    Evidence-based recommendations on ramucirumab (Cyramza) for locally advanced or metastatic non-small-cell lung cancer in adults who have had platinum-based chemotherapy.

  4. Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban (TA697)

    Evidence-based recommendations on andexanet alfa (Ondexxya) for reversing anticoagulation form apixaban or rivaroxaban in adults with life-threatening or uncontrolled bleeding.

  5. Pre-hospital initiation of fluid replacement therapy in trauma (TA74)

    Evidence-based recommendations on giving intravenous (IV) fluid replacement therapy for people with serious injuries before reaching hospital.

  6. Virtual ward platform technologies for acute respiratory infections (HTE13)

    Early value assessment (EVA) guidance on virtual ward platform technologies for acute respiratory infections....

  7. Erectile dysfunction: Alprostadil cream (ESNM50)

    Summary of the evidence on alprostadil cream for treating erectile dysfunction to inform local NHS planning and decision-making

  8. Bortezomib monotherapy for relapsed multiple myeloma (TA129)

    Evidence-based recommendations on bortezomib monotherapy (Velcade) for treating relapsed multiple myeloma in adults.

  9. Regorafenib for previously treated advanced hepatocellular carcinoma (TA555)

    Evidence-based recommendations on regorafenib (Stivarga) for treating advanced hepatocellular carcinoma in adults who have had sorafenib.

  10. Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (TA275)

    Evidence-based recommendations on apixaban (Eliquis) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.

  11. Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer (TA737)

    Evidence-based recommendations on pembrolizumab (Keytruda) with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer in adults.

  12. Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies (TA819)

    Evidence-based recommendations on sacituzumab govetican (Trodelvy) for treating unresectable, triple-negative locally advanced or metastatic breast cancer in adults after 2 or more systemic therapies, at least 1 of which was for advanced disease.

  13. Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (TA422)

    Evidence-based recommendations on crizotinib (Xalkori) for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults.

  14. Parafricta Bootees and Undergarments to reduce skin breakdown in people with or at risk of pressure ulcers (MTG20)

    Evidence-based recommendations on Parafricta Bootees and Undergarments to reduce skin breakdown in people with or at risk of pressure ulcers.

  15. Library and knowledge services staff

    ebooks. Find out how to register, who your administrator is and eligibility criteria. View OpenAthens support and information OpenAthens...